Drug Profile

RG 6289

Alternative Names: RG-6289

Latest Information Update: 22 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Class Antidementias
Mechanism of Action Amyloid precursor protein secretase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alzheimer's disease

Most Recent Events

14 Nov 2024 Banner Alzheimers Institute and Neurosciences Group at the University of Antioquia (GNA) in Medellin plans a clinical trial for Alzheimer's-disease (Monotherapy, Prevention, In adults), in fall 2025 (IV)
14 Aug 2024 Phase-II clinical trials in Alzheimer's disease (unspecified route) (Roche pipeline, August 2024)
28 Jul 2024 Roche completes a phase I trial in Alzheimer's disease (In volunteers) (unspecified route) prior to July 2024 at an unknown location

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com